Intelligence Platform

Patents

Browse 379 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11034957

Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11034958

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11028392

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10995336

Serpina1 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10988768

TMPRSS6 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10982215

Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of us

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10982212

Conserved HBV and HCV sequences useful for gene silencing

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10968452

Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954516

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946107

Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10933081

Myostatin iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934544

Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and k

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934545

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10920223

Serpina1 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10913950

TMPRSS6 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10889813

Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10883107

Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use there

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10851377

Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gen

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10844384

Glucokinase (GCK) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10829763

TMPRSS6 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10814007

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10808246

Oligonucleotide-ligand conjugates and process for their preparation

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10806791

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10767177

Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and m

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted